Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: Mass Spectral Fragmentation Analysis SOP – V 2.0

Posted on By

Analytical Method Development: Mass Spectral Fragmentation Analysis SOP – V 2.0

Standard Operating Procedure for Mass Spectral Fragmentation Analysis in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/108/2025
Supersedes SOP/AMD/108/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP describes the procedure for conducting mass spectral fragmentation analysis to aid in structural elucidation, impurity identification, and degradation product profiling in pharmaceutical R&D using LC-MS/MS or

GC-MS/MS systems.

2. Scope

This SOP applies to all mass spectral analyses involving fragmentation studies of small molecules in Analytical Method Development (AMD) laboratories using tandem mass spectrometry (MS/MS) platforms.

3. Responsibilities

  • Analytical Scientist: Performs fragmentation studies, interprets MS/MS spectra, and proposes fragmentation pathways.
  • MS Specialist: Assists in instrument configuration and data processing setup.
  • QA Officer: Reviews documentation and ensures compliance with scientific and regulatory standards.
  • Head – AMD: Approves final fragmentation reports and ensures alignment with development objectives.

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that fragmentation analysis supports method development, impurity identification, and is carried out as per regulatory expectations.

See also  Analytical Method Development: SOP for Analytical Method for Liposomes - V 2.0

5. Procedure

5.1 Sample and Standard Preparation

  1. Weigh and dissolve 1–2 mg of analyte in 1 mL of appropriate solvent (acetonitrile, methanol, or water).
  2. Filter through 0.22 µm PVDF or PTFE filters before injection.
  3. If studying degradation or impurities, prepare stress-degraded samples using acid, base, oxidative, thermal, or photolytic conditions.
  4. Document sample prep in Annexure-1: Sample Preparation Log.

5.2 Instrument Configuration

  1. Use triple quadrupole or Q-TOF MS systems with Electrospray Ionization (ESI) or APCI interface.
  2. Configure precursor ion scan (Q1), fragment scan (Q3), and collision energy ramp.
  3. Set up scan modes:
    • Full scan MS (Q1 scan)
    • Product ion scan (MS/MS)
    • Neutral loss scan (optional)
  4. Document instrument settings in Annexure-2: Instrument Configuration Sheet.

5.3 Acquisition and Optimization

  1. Inject 10 µL of sample into LC-MS/MS system using validated chromatographic conditions.
  2. Record full scan spectra to identify parent ion (m/z of interest).
  3. Apply varying collision energies (e.g., 10–40 eV) in product ion mode.
  4. Capture fragment spectra at multiple energies for robust pathway analysis.
  5. Repeat for positive and negative ion modes if applicable.
  6. Record parameters and spectra in Annexure-3: Fragmentation Data Log.
See also  Analytical Method Development: SOP for Preparation and Approval of Working Standards - V 2.0

5.4 Interpretation of Fragment Ions

  1. Identify major fragment ions and determine:
    • Neutral losses (e.g., H2O, CO, CH3OH)
    • Stable ring cleavages or chain fragmentations
    • Rearrangement ions or diagnostic ions
  2. Use chemical structure drawing software to propose fragmentation pathways.
  3. Label fragmentation positions and correlate with known chemical logic.
  4. Prepare pathway diagrams in Annexure-4: Fragmentation Scheme Sheet.

5.5 Reporting and Documentation

  1. Summarize:
    • Precursor ion and major fragments with m/z values
    • Collision energy and scan parameters
    • Fragmentation mechanism and structural rationale
  2. Include:
    • Annotated MS/MS spectra
    • Structure with fragmentation arrows
    • Conclusion on identity or impurity assignment
  3. Compile into final report and submit for review.
  4. Record final documentation in Annexure-5: Summary Report Log.

6. Abbreviations

  • MS/MS: Tandem Mass Spectrometry
  • Q-TOF: Quadrupole Time of Flight
  • ESI: Electrospray Ionization
  • APCI: Atmospheric Pressure Chemical Ionization
  • SOP: Standard Operating Procedure

7. Documents

  1. Sample Preparation Log – Annexure-1
  2. Instrument Configuration Sheet – Annexure-2
  3. Fragmentation Data Log – Annexure-3
  4. Fragmentation Scheme Sheet – Annexure-4
  5. Summary Report Log – Annexure-5

8. References

  • ICH Q3A/B – Impurities Guidelines
  • FDA Guidance on Mass Spectrometry for Structural Elucidation
  • Instrument Manufacturer Manuals for QqQ and Q-TOF Systems
See also  Analytical Method Development: SOP for Qualification of Chromatographic Columns - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Sample Preparation Log

Sample ID Solvent Concentration Filter Type Prepared By Date
MSF-108-A Methanol 1 mg/mL PTFE 0.22 µm Rajesh Kumar 18/05/2025

Annexure-2: Instrument Configuration Sheet

Instrument Ion Source Mode Collision Energy Range Scan Type
Q-TOF LC-MS ESI Positive 10–40 eV Product Ion Scan

Annexure-3: Fragmentation Data Log

Precursor Ion (m/z) Major Fragments (m/z) Collision Energy Comments
332.1 287.0, 149.1, 121.0 30 eV Consistent with expected cleavage

Annexure-4: Fragmentation Scheme Sheet

[Attach hand-drawn or software-generated fragmentation pathways showing bond cleavage sites and resulting ion structures.]

Annexure-5: Summary Report Log

Sample Analysis Type Result Summary Analyst Approved By
Compound X Impurity Structure Elucidation Identified 2 degradants via MS/MS Sunita Reddy Head – AMD

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Expanded MS/MS modes and fragmentation scheme annexure Annual SOP Update
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: API Manufacturing: SOP for Management Review of Quality Metrics – V 2.0
Next Post: Elixir Department: SOP for Control of Alcohol Evaporation Loss – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version